Clinical trials
Age Related Cataracts clinical trials
Below are recruiting age related cataracts clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07249216Recruiting
Eye fluid study for wet AMD treatment response
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
SingaporeAges 50 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT06351670Recruiting
Monitoring early to moderate age-related macular degeneration with AI
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
ViennaAges 55–99 - NCT06351657Recruiting
Monitoring macular degeneration with AI to detect progression
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
ViennaAges 55–99 - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Mesa, ArizonaAges 50 years+ - NCT06604104Recruiting
Visual Frailty Study in Older Adults with AMD
This study looks at something called 'visual frailty' in older adults with advanced age-related macular degeneration (AMD). It aims to develop a tool to better understand how vision loss affects daily life and overall health in people aged 60 and over.
Edinburgh, ScotlandAges 60 years+ - NCT06952452RecruitingPhase 3
Testing genes to improve AMD treatment
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
San Cristóbal de La Laguna, Santa Cruz De TenerifeAges 50 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06619405Recruiting
Eye Function Test for Age-Related Macular Degeneration
This study tests a quick, noninvasive eye test that measures how well you see in the dark, which can be an early sign of dry AMD. Researchers want to see if the test relates to everyday tasks like reading or driving at night.
Durham, North CarolinaAges 50–89 - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Phoenix, ArizonaAges 50 years+ - NCT07005323Recruiting
New treatment for resistant wet AMD
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
Ube, YmaguchiAges 50–85 - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT04504123RecruitingPhase 2
Doxycycline eye treatment for persistent wet macular degeneration fluid
This trial tests whether an “MMP-9 inhibitor” medicine given as doxycycline (a tetracycline-type antibiotic) can reduce persistent leaking and fluid in wet age-related macular degeneration. It may help people whose wet AMD is not fully controlled even after several anti-VEGF injections.
Iowa City, IowaAges 50–99 - NCT04663750RecruitingPhase 3
Surgery to treat bleeding under the retina in wet macular degeneration
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
BonnAges 50–120 - NCT04847635Recruiting
Laser test for aging-related macular spots under the retina
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
GenovaAges 55 years+ - NCT05438732Recruiting
Test of an implanted eye device plus vision training for AMD
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Loma Linda, CaliforniaAges 65 years+ - NCT05465252Recruiting
Omega-3 supplement to slow early dry macular degeneration
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
ShanghaiAges 50–85 - NCT05626114RecruitingPhase 2
Study of a lab-made eye treatment after subretinal surgery
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
Beverly Hills, CaliforniaAges 50 years+
Hear when a new Age Related Cataracts trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for age related cataracts?
- Yes. Clin2 currently lists 62 recruiting age related cataracts studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a age related cataracts trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a age related cataracts trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Age-related Cognitive Decline
- Age-related Hearing Loss
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.